// App-Quantinova.ai

: Quality-of-Life Outcomes in Patients with Relapsed/Refractory Multiple Myeloma Treated with Elotuzumab Plus Pomalidomide and Dexamethasone: Results from the Phase 2 Randomized Eloquent-3 Study

Researchers

Presenter

  • Katja Weisel

Principal Investigators

  • Agne Paner

  • Monika Engelhardt

  • Fiona Taylor

  • Kim Cocks

  • Ashlee Espensen

  • Mihaela Popa-McKiver

  • Clara Chen

  • Michele Cavo

Medical Centers

  • University Hospital Tübingen,Tübingen,Germany

  • Rush University Medical Center, Chicago, IL

  • University Medical Center Freiburg, Freiburg, Germany

  • Adelphi Values, Boston, MA

  • Adelphi Values, Bollington, United Kingdom

  • Bristol-Myers Sqiubb, Princeton, NJ

  • Bologna University School of Medicine, Bologna, Italy

Locations

  • Germany

  • United States

  • United Kingdom

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Pomalidomide

  • CC-4047

  • Elotuzumab

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • II

Study Id's

  • NCT02654132

Sponsors

  • Bristol-Myer Squibb

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved